North Carolina Hematologic Malignancies Symposium
Overview
The North Carolina Hematologic Malignancies Symposium aims to enhance participants’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize outcomes for patients with hematologic malignancies. Through scientific debates, panel discussions, and in-depth analysis, the conference will address key controversies and advances in the field, with a focus on integrating innovative therapies into clinical practice. Designed for a multidisciplinary audience of physicians, advanced practice providers, pharmacists, nurses, and other healthcare professionals, the conference emphasizes evidence-based approaches and a patient-centered care model. Participants will gain actionable insights to improve clinical outcomes and stay informed on the latest developments in hematologic malignancies.
Target Audience
- Medical oncologists and hematologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Organizing Committee
Course Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Chair
Deborah Stephens, DO - University of North Carolina, Chapel Hill
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
Program
Saturday, June 7th, 2025
All times below are listed in Eastern Standard Time (EDT).
07:30 AM – 08:30 AM Registration, Breakfast, & Exhibits
08:30 AM – 08:45 AM Welcome and Introduction to Binaytara Foundation - Binay Shah, MD, MHA
08:45 AM – 09:45 AM Session 1: Lymphoma
Session Chair: Nilanjan Ghosh, MD, PhD
08:45 AM – 09:00 AM Frontline Treatment of Advanced Stage Hodgkin Lymphoma -
09:00 AM – 09:15 AM Frontline Treatment of Mantle Cell Lymphoma -
09:15 AM – 09:25 AM Case #1: Relapsed Follicular Lymphoma -
09:25 AM – 09:35 AM Case #2: Relapsed Diffuse Large B-Cell Lymphoma -
09:35 AM – 09:45 AM Case #3: Newly Diagnosed T-Cell Lymphoma -
09:45 AM - 10:45 AM Session 2: Chronic Lymphocytic Leukemia
Session Chair: Deborah Stephens, DO
09:45 AM – 10:00 AM Selection of Frontline Therapy for CLL - Deborah Stephens, DO
10:00 AM – 10:15 AM Second Line Therapy after Venetoclax + Obinutuzumab -
10:15 AM – 10:30 AM Strategy for 3rd Line and Beyond Treatment of CLL -
10:30 AM – 10:45 AM Beyond 3rd Line, Promising Novel Treatments -
10:45 AM - 11:15 AM Break & Exhibits
11:15 AM - 12:15 PM Session 3: Multiple Myeloma
Session Chair: Raymond Thertulien, MD, PhD
11:15 AM – 11:30 AM Management Strategies for Patients with Newly Diagnosed Multiple Myeloma - Transplant-Ineligible -
11:30 AM – 11:45 AM Bispecific Antibodies and CART for Multiple Myeloma -
11:45 AM – 11:55 AM Case #1: Smoldering Myeloma - To Treat or Not to Treat -
11:55 AM – 12:05 PM Case #2: Triplets Versus Quadruplets in Frontline MM -
12:05 PM – 12:15 PM Case #3: Immunotherapy in Relapsed MM -
12:15 AM - 01:15 PM Lunch & Exhibits
01:15 PM - 02:15 PM Session 4: Acute Myeloid Leukemia
Session Chair: Josh Zeidner, MD
01:15 PM – 01:30 PM Frontline Treatment for Younger/Fit AML -
01:30 PM – 01:45 PM Frontline Treatment for Older AML -
01:45 PM – 02:00 PM Novel Targeted Therapy Approaches in AML - Menin Inhibitors -
02:00 PM – 02:15 PM Incorporating FLT3 Inhibitors in AML -
02:15 PM - 03:15 PM Session 5: Myeloproliferative Neoplasms
Session Chair: Lindsay Rein, MD
02:15 PM - 02:30 PM Thrombosis Management in MPNs -
02:30 PM – 02:45 PM Novel Therapeutic Strategies in PV: Moving Beyond Phlebotomy -
02:45 PM – 02:55 PM Case #1: Essential Thrombocytosis Versus Pre-Fibrotic MF
02:55 PM – 03:05 PM Case #2: Myelofibrosis - Tailoring JAK Inhibitor Choices to Individual Patients -
03:05 PM – 03:15 PM Case #3: Myelofibrosis - Drug Interactions Between MPN-Directed Therapies and Commonly Used Medications -
03:15 PM Adjourn
Venue
Faculty
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Deborah Stephens, DO
Nilanjan Ghosh
Accreditation
Available Credit
- 5.00 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 5.00 ACPE Pharmacy
The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The ACPE Universal Activity Number assigned to the activity is
Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.
The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.
After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.
- 5.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 5.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.00 Contact Hours.
Exhibitors
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Register/Take course
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.